The Asia-Pacific dipeptidyl peptidase 4 (DPP-4) inhibitors market is anticipated to grow significantly at a CAGR of 3.5% over the forecast period (2020-2026). China, India, Japan, ASEAN, South Korea, and the Rest of Asia-Pacific are the major countries contributing to the growth of the Asia-Pacific dipeptidyl peptidase 4 (DPP-4) inhibitors industry over the forecast period. The high prevalence of diabetes among the people in the region further supports the market growth. As per the International Diabetes Federation, over 250 million people in the region suffer from diabetes. Among these major economies of the region, China, India, and Japan are the most affected countries. China has the highest prevalence of diabetes in 2019 with around 116 million, India has the second-highest prevalence of diabetes followed by Japan, which significantly contributes to market growth.
Browse the full report description of "Asia-Pacific Dipeptidyl Peptidase 4 (DPP-4) Inhibitors Market Size, Share & Trends Analysis Report by Drug Type (Sitagliptin, Vildagliptin, Saxagliptin, Linagliptin, Gemigliptin, Anagliptin, Teneligliptin, and Others) Forecast, 2020-2026" at https://www.omrglobal.com/industry-reports/asia-pacific-dipeptidyl-peptidase-4-inhibitors-market
Some major factors that lead to diabetes in the region are the sedentary lifestyles of the people, the consumption of junk food which leads to obesity, and the rising geriatric population. Hence, such aforementioned factors lead to diabetes in the people which in turn creates a wide scope for the growth of the Asia-Pacific dipeptidyl peptidase 4 (DPP-4) inhibitors market. Some of the drugs available and approved in the region include Gemigliptin approved in Korea by LG Life Sciences; Anagliptin approved in Japan by Sanwa Kagaku Kenkyusho Co., Ltd., and Kowa Company, Ltd; Trelagliptin, Teneligliptin approved in Japan; and Evogliptin approved for use in South Korea. Hence, such factors are considered to be as growth aspects for the market in the Asia-Pacific region.
Market Coverage
Key questions addressed by the report
o Recovery Timeline
o Deviation from pre-COVID forecast
o Most affected segment
Asia-Pacific Dipeptidyl peptidase 4 (DPP-4) inhibitors Market – Segmentation
By Type
Asia-Pacific Dipeptidyl peptidase 4 (DPP-4) inhibitors Market – Countries Covered
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/asia-pacific-dipeptidyl-peptidase-4-inhibitors-market